Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.109 -0.271 (-4.25%) Market Cap: 941.56 Mil Enterprise Value: 838.75 Mil PE Ratio: 0 PB Ratio: 4.20 GF Score: 81/100

Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference Transcript

Jan 10, 2022 / 06:30PM GMT
Release Date Price: $21.95 (-5.27%)
Tycho W. Peterson
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon. I'm Tycho Peterson. It's my pleasure to introduce our next company today, Adaptive Biotechnologies. Just a quick reminder, if people have questions or submit question function on the website. And with that, I'll turn it over to Chad.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thank you, Tycho, and thanks for the opportunity to present at JPMorgan and also Happy New Year to you.

So welcome, everyone, to the Adaptive Biotechnologies' presentation. We are the leading company in harnessing the power of the Adaptive immune system, and we're going to do so in a number of important ways, which I'm excited to share with you today. Throughout the pandemic, the world got a crash course in the adaptive immune system and the role that T cells play in fighting disease. We saw countless publications and articles highlighting the relevance of antibodies and of T cells in immunity. At Adaptive, that's exactly what we're focused on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot